The bioavailability problem Absorption comparison: Injection: 80-100% bioavailability (nearly all absorbed) Nasal spray: 30-70% bioavailability (varies by peptide) Oral: 0-5% bioavailability (most peptides destroyed) Why nasal lower than injection: Must penetrate nasal mucosa (barrier) Some drips down throat (swallowed = lost) Variable absorption efficiency Technique-dependent Individual variation high What this means: You need MORE peptide via nasal spray Typically 2-3x higher dose than injection Example: 1mg injection = 2-3mg nasal Increases cost significantly But still cheaper/easier than injection for some Conversion guidelines by peptide PT-141: Injection: 1.5-2mg typical dose Nasal equivalent: 3-5mg Conversion ratio: 2-3x Semax: Designed for nasal use (no conversion needed) Standard nasal dose: 200-600mcg per spray 2-3 sprays per nostril typical Follow product guidelines BPC-157 (if attempting nasal): Injection: 250-500mcg Nasal (estimated): 750-1500mcg But: Injection or oral likely better Nasal BPC-157 not well-studied General conversion approach: Start with 2-3x injection dose Assess results after 2-3 uses Increase by 25-50% if weak effects Find minimum effective nasal dose Individual variation significant Cost implications: Using 2-3x more peptide = 2-3x cost Nasal spray more expensive per dose Trade-off: Convenience vs cost Worth it for needle-phobic Not worth it if injections acceptable Use peptide cost calculator to compare routes
However, it is crucial to carefully vet vendors for certification, reputation, and quality control measures
The study discussed here was relatively small, involving only 17 patients, and more extensive clinical trials are needed to fully understand: Long-term safety profile Optimal dosing protocols Patient selection criteria Potential side effects Interactions with other treatments Additionally, patients should be aware that BPC-157 is not yet FDA-approved for human use, and treatment is typically offered on a research or compassionate use basis by qualified practitioners
Gastrointestinal symptoms represent a likely indirect cause of sleep disruption
10.1007/s10989-017-9641-1 323 ZeinN.YassinF.EldeenE.ElshorbagyI
Bolton WD, Rice DC, Goodyear A, Correa AM, Erasmus JJ, Hofstetter WL, Komaki R, Mehran RJ, Pisters K, Roth JA, Swisher SG , Vaporciyan AA, Walsh GL, Weaver J, Rhines L
